ZYBERNO
Stock Report
Updated Aug 23, 2026

KAYA HOLDINGS, INC. (KAYS)

Healthcare • OTC

$0.00

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
11.0/100
POOR BUSINESS
KAYA HOLDINGS, INC. (KAYS) scores 11/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (0.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (-3,465.4%)
Return on Capital (Capital Efficiency):CRITICAL (0.0%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

KAYA HOLDINGS, INC. (KAYS) stock report — Zyberno Score 11/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:0.00
Market Cap:$68.64K

Valuation Multiples (2)

P/S Ratio:2.57x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$502.07K
B. Profitability Assessment

Return Metrics (1)

ROA:-5,404.2%

Margin Analysis (3)

Operating Margin Ttm:-3,465.4%
Net Margin Ttm:-46,551.8%
Ebitda Margin:-3,439.6%

TTM Performance (3)

Gross Margin Ttm:28.9%
Operating Margin Ttm:-3,465.4%
Net Margin Ttm:-46,551.8%

Yield Metrics (2)

Earnings Yield:-$260.00K
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:67.4%
Latest Earnings Filed:2025-11-20

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):-50.0%

Earnings Growth (Linear) (1)

Net Income Growth Rate (Linear):-50.0%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:0.04x
Quick Ratio:0.04x
Cash Ratio:0.10x

Leverage Analysis (1)

Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:-2,422,383.00
Cash And Cash Equivalents:250,000.00
Long Term Debt:$0.00
Net Debt:$433.43K
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $26.69K
Linear Growth: -50.0%
📊 Click to view full KAYS Revenue analysis & methodology →
Cost Of Revenue Ttm:$18.97K

Profitability Breakdown (2)

Gross profit TTM: $7.72K
Linear Growth: -50.0%
📊 Click to view full KAYS Gross Profit analysis & methodology →
-$924.94K

Bottom Line Performance (3)

Net income TTM: -$12.43M
Linear Growth: -50.0%
📊 Click to view full KAYS Net Income analysis & methodology →
Income Before Tax:-$12.44M
Ebitda Ttm:-918,074.00

Operating Expenses (5)

Operating Expenses:918,059.00
R And D Expense:0.00
Sga Expense:291,259.00
Income Tax Expense:$19.67K
Interest Expense:0.00

Expense Ratios (3)

R And D To Revenue Percentage:0.0%
Sga To Revenue Percentage:5,385.7%
Ebitda Margin:-3,439.6%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$199.36K
Current Assets:$111.69K
Ppe Net:22,600.00
Goodwill:26,395.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:2,919,815.00
Current Liabilities:2,534,073.00
Long Term Debt:$0.00
Short Term Debt:$683.43K

Equity & Capital (3)

Equity:-$2.72M
Retained Earnings:-$51.24M
Common Stock:1,500,000,000.00

Working Capital Items (3)

Accounts Receivable:11,735.00
Inventory:348.00
Accounts Payable:683,427.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:0.00
C. Cash Flow Analysis

Operating Activities (2)

-$836.18K-$853.83K

Investment Activities (2)

Investing Cash Flow:$2.13K
Capital Expenditures Ttm:17,643.00

Financing Activities (3)

Financing Cash Flow:$195.00K
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:6,868.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-0.26
-$0.26
Earnings Per Share Ttm:-$0.02

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.00
Operating Cash Flow Per Share:-$0.00

Book Value & Capital (2)

Book Value Per Share:-$0.00
Cash Per Share:0.00

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.12x
Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:2.27x
Days Sales Outstanding Ttm:160.48

Inventory Management (2)

Inventory Turnover Ttm:54.51x
Days Inventory Outstanding Ttm:6.70

Payables & Cash Cycle (2)

Days Payable Outstanding:13,149.06
Cash Conversion Cycle:-12,981.89
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:20.00
Quality Score:20.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (2)

Revenue Growth Rate (Linear):-50.0%
Net Income Growth Rate (Linear):-50.0%

Other Growth Rates (1)

Gross Profit Growth Rate (Linear):-50.0%
C. Company Profile & Context

Corporate Information (6)

Symbol:KAYS
Company Name:KAYA HOLDINGS, INC.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:OTC
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:penny
Volume Category:N/A

Share Structure (3)

Shares Outstanding:686.44M
Shares Outstanding Basic:147.81M
Shares Outstanding Diluted:147.81M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-23 01:58:17 UTC
Data Timestamp:2026-08-21T16:25:05.292066
Scroll to Top